The acquisition was disclosed in a filing with the SEC, which is available at the SEC website ... target for the company. Truist Financial decreased their target price on Pfizer from $36.00 ...

Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX® ) and mFOLFOX6 ...

Reported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL at the 66th ...

Vortex Biotech Holdings, (‘Vortex’, or ‘the Company’), a leading oncology liquid biopsy company, is pleased to announce the appointment of Nigel Brooksby as Non-Executive Chairman. Nigel is an ...

Juro, a contract automation platform leveraging artificial intelligence, has announced the opening of its US headquarters in ...

Dubai, UAE: MSD, a leading biopharmaceutical company, has established a new office in Dubai, further solidifying its ...

FDA approved Ryoncil ® as the first and only therapy for pediatric patients 2 months and older, including adolescents and teenagers, with steroid-refractory acute graft versus host disease (SR-aGvHD), ...

Already competing to bring the first vaccine against respiratory syncytial virus (RSV) to market, Pfizer ... Law360.com website. GSK's vaccine has just hit the mark in a phase 3 trial, and the ...

The former 1960s office tower at 25 Water Street, once home to JPMorgan Chase and the New York Daily News, is now a luxury ...

Total proceeds of $530 million on $300 million original 2022 investment Proceeds strengthen balance sheet and provide added flexibility to pursue disciplined capital allocation strategy, including sig ...